期刊文献+

缬沙坦降压、逆转肾性高血压大鼠左室肥厚和对血小板聚集率的影响 被引量:1

The Effects of Valsartan on Systolic Blood Pressure, Left Ventricular Hypertrophy and Blood Platelet Aggregation in Renovascular Hypertensive Rats
下载PDF
导出
摘要 目的 :观察血管紧张素 的 1型 (AT1 )受体拮抗剂缬沙坦与血管紧张素转换酶抑制剂依那普利对肾性高血压左室肥厚大鼠血压、心肌重量及对血小板聚集率的影响。方法 :建立两肾一夹 (Goldblott)肾性高血压大鼠致左室肥厚模型。大鼠左室肥厚形成后 ,缬沙坦与依那普利灌胃给药连续 12周 ,观察两药对大鼠血压、心肌重量和血小板聚集率的影响。结果 :大鼠左侧肾动脉部分钳夹后 ,其收缩压、左心室湿重与体重的比值及血小板聚集率均高于正常对照组。在大鼠左室肥厚形成后 ,缬沙坦与依那普利连续给药 12周 ,可显著降低收缩压、左心室湿重与体重的比值 ,抑制血小板聚集率。结论 :肾性高血压大鼠左室肥厚形成后 ,缬沙坦与依那普利长期给药 ,具有降压。 Objective:To investigate the effects of Valsartan (a sort of nonheterocyclic angiotensin Ⅱ antagonist) and Enalapril on systolic blo od pressure(SBP), left ventricular hypertrophy(LVH) and blood platelet aggregati on in renovascular hypertension rats(RHR).Methods:Establish the mode l of RHR with LVH by clipping the left renal artery (two kidneys, one clip model ). Eight weeks later,Valsartan and Enalapril were given by perfusing stomach to rats daily for twelve weeks to examine the affects on SBP, LVH and blood platele t aggregation. Results: After twenty weeks of clippling of the left renal artery,the SBP,the ratio of left ventricar wet weight/body weight(LVWW/BW) and blood platelet aggregation were more increased than those in the control gro up. Twelve weeks treatment of valsartan and Enalapril can decrease SBP, LVWW/BW and blood platelet aggregation on RHR with LVH.Conclusion:Both Valsartan and Enalapril have regressive effects and ca n decrease blood pressure and blood platelet aggregation.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2001年第2期85-87,98,共4页 Journal of Nanjing Medical University(Natural Sciences)
基金 江苏省教委自然科学基金资助项目 (KJD32 0 0 0 5)
关键词 缬沙坦 依那普利 左室肥厚 血小板聚集率 药物疗法 valsartan enalapril left ventricular hypertrophy blo od platelet aggregation
  • 相关文献

参考文献3

  • 1Li J,Atherosclerosis,1999年,143卷,2期,315页
  • 2Hulthen U L,Am Hypertens,1996年,9卷,9期,895页
  • 3Linz W,Clin Exp Hyperten,1989年,11卷,1325页

同被引文献26

  • 1胡艳茹.非肽类血管紧张素Ⅱ受体拮抗剂——洛沙坦[J].华北药学,1999,10(2):24-24.
  • 2刘健 李春江 张宏伟 等.缬沙坦对支架后新生内膜增生抑制作用的实验研究[J].药物与临床,1999,14(6):7-10.
  • 3Owens DR. Repaglinide--prandial glucose regulator,a new class of oral antidiabetic drugs [J]. Diabeted,1998,15(supp1 4) :28.
  • 4Timmermans PB. pharmacokinetics of antiotensin I(AT1) recept or antagonists [J]. Car J cardiol, 1999,15(suppl F) :26.
  • 5Israili ZH. Clinical pharmacokinetics of angiotensin I receptor blockers in hypertension [ J ]. J. Hum Hypertens, 2000,14 (suppl 1 ) : 73.
  • 6Oparil S. Newly emerging pharmacologic differences in angiotensin I receptor blockers [J]. Am J Hypertens, 2000,13 (2):18.
  • 7Shokei kim,Yumei zhan,Yasukatsu zsumi. Cardiovascular Effects of combination of perindopril,candesartan, and Amlodipine in Hypertensive Rats [J].Hypertension, 2000,2000 (4) : 769.
  • 8Hernandez Hernandez R, Velasco M, Armas Hernandez MJ,et al. Angiotensin I receptor antagonists in arterial hypertension [J]. J Hum Hypertens,2000,14(suppl 1 ) :69.
  • 9Qin-Gui Xia, Oliver chung, Thomas unger.significance of Timing of Angiotensin AT1 Receptor Blockade in Rats with Myocardial infarction-induced Heart Failure[J]. Cardiovascular Research, 2001,49(1):10.
  • 10Jain M ,Liao R,Ngoy s ,Anglotensin I receptor blockadl attenuates the deleterions effects of exercise training on post-MI ventricular remodelling in Rats [J].Cardiovasc Res, 2000,46(1):66.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部